Clinical Trials

376 enrolled

Phase 2 Not yet recruiting

Esophageal Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT07007182 2025-09-05

Conversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric Cancer

54 enrolled

Stomach Neoplasms

NCT06255223 2025-09-03

A Study of Multimodal Radiotherapy for Renal Cell Carcinoma Progressed After Prior Immunotherapy

35 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT05576480 2025-08-28

SPARC

55 enrolled

Phase 2 Not yet recruiting

Rectal Neoplasms

NCT07053150 2025-07-08

CCGLC-018

80 enrolled

Advanced Digestive System Tumor

NCT06728657 2025-06-18

TORCH-G

Phase 2 Suspended

68 enrolled

Stomach Adenocarcinoma

NCT06013618 2025-06-17

Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma

120 enrolled

CNS

Neuroblastoma

NCT04821765 2025-05-30

Study of PD-1 Antibody Combined With Chemoradiotherapy in Oligometastatic Esophageal Cancer

Phase 2 Completed

35 enrolled

Esophageal Neoplasms

NCT06908031 2025-05-14

CRIT

49 enrolled

Rectal Neoplasms

NCT06437509 2025-05-07

A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Extensive-stage Small Cell Lung Cancer

66 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT06437522 2025-05-07

A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors

46 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT06471205 2025-05-07

A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast Cancer

52 enrolled

Breast

Triple Negative Breast Neoplasms

NCT06928584 2025-04-15

Hypofractionated Radiotherapy Plus Immunotherapy Versus Conventional Radiotherapy in Locally Recurrent Rectal Cancer

221 enrolled

Phase 2 Active not recruiting

Locally Recurrent Rectal Cancer

NCT04802876 2025-03-21

ACROPOLI

184 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmSarcomaThoracic

Adenocarcinoma Of Esophagus, Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Uveal Melanoma, Anus Neoplasms, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Mesothelioma, Neoplasms, Unknown Primary, Sarcoma, Thyroid Neoplasms, Cholangiocarcinoma, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT04866836 2025-03-21

A Study of Tislelizumab Combined With Radiotherapy as the Second-line Treatment of Advanced Biliary Malignant Tumors

20 enrolled

Cholangiocarcinoma

NCT06758037 2025-03-18

HiR+X

50 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT06840665 2025-02-21

MR-guided Adaptive Radiotherapy Combined With PD-1 Antibody and CAPOX for Locally Advanced Rectal Cancer

46 enrolled

Locally Advanced Rectal Cancer

NCT03991130 2025-02-06

High Dose IL-2 in Combination With Anti-PD-1 to Overcome Anti-PD-1 Resistance in Metastatic Melanoma and Renal Cell Carcinoma

DermatologicGenitourinary

6 enrolled

Carcinoma, Renal Cell, Melanoma, Neoplasm Metastasis

NCT06792162 2025-01-24

PD-1 Antibody Carilizumab Combined with Apatinib for Unresectable Stage III and IV DMMR Gastric Cancer

20 enrolled

Stomach Neoplasms

NCT04518280 2025-01-17

TORCH

Phase 2 Completed

130 enrolled

NCT05555888 2025-01-15

TORCH-E

34 enrolled

Early Low Rectal Cancer

NCT05972655 2025-01-09

mRCAT

32 enrolled

Low Rectal Cancer

NCT04310397 2024-10-30

Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D Melanoma

Phase 2 Not yet recruiting

4 enrolled 8 charts

Dermatologic

Melanoma

NCT06665087 2024-10-30

CGA Guided Ultrafractionated RT and First-line Systemic Treatment in Elderly or Frail Patients with MCRC

110 enrolled

Phase 2 Active not recruiting

Colonic Neoplasms, Rectal Neoplasms

NCT05522582 2024-10-26

Methotrexate Combined With Immunotherapy During Radiotherapy for Solid Tumors

50 enrolled

Other solid neoplasm

Solid Tumors

NCT03207867 2024-10-09

A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma